Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Q-Line Biotec IPO
Price Band
₹326.0–343.0
Issue Size
₹214.48 Cr
Lot Size
400 shares
Min Investment
₹274,400
2 LOTS MIN
GMP
+₹112.0 (32.65%)
Issue Price
₹343.0
Q-Line Biotec IPO AI Summary
- Q-Line Biotec IPO is listed on NSE SME in the Medical Equipment & Supplies sector.
- Price band: ₹326.0–₹343.0 per share, lot size 400 shares (min. investment ₹274,400, 2 lots minimum).
- Subscription window: 21 May–25 May 2026, listing on 29 May 2026.
- Current GMP is +₹112.0 (32.65%), an estimated listing price of ₹455 — unofficial and can change daily.
Q-Line Biotech Ltd. is set to offer its shares in an IPO with a price band of ₹326.0 to ₹343.0. The company has shown growth in total income and profit over the past few years, with a strong focus on the IVD market. Investors should consider the associated risks and their investment strategies before participating.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Q-Line Biotec IPO Grey Market Premium (GMP) Today
GMP
+₹112.0
GMP %
+32.65%
Est. Listing
₹455.0
Updated: 14 Jul 2026 15:51
About the Company
Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company's key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. As of March 31, 2025, the company had 313 permanent employees. Competitive Strengths: Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control. Diversified product portfolio with focus on IVD industry Widespread distribution network with a presence across all four regions. Long standing relationships with customers. Experienced Promoter and Management team
Company Financials (₹ Cr)
As of 2025-12-31
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 561.34 | 455.49 | 339.25 | 251.58 |
| Total Income | 236.50 | 322.58 | 206.45 | 184.81 |
| Profit After Tax | 38.69 | 28.13 | 34.44 | 32.10 |
| EBITDA | 64.23 | 71.32 | 37.63 | 32.98 |
| NET Worth | 229.16 | 189.95 | 161.81 | 127.37 |
| Reserves and Surplus | 212.89 | 188.37 | 160.24 | 125.79 |
| Total Borrowing | 243.85 | 164.95 | 96.91 | 73.65 |
Key Ratios
EPS
₹16.47
NAV
₹120.60
ROE
23.74%
ROCE
17.66%
RoNW
23.74%
P/B Value
2.84
P/E Ratio
20.82
Market Cap
₹800.16 Cr
PAT Margin
8.97%
Debt/Equity
0.87
Promoters
Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 To meet working capital requirements 93.50 2 Repayment of certain borrowing availed by the Company, in part or full 90.00 3 General Corporate Purposes 5.10 4 Issue Expenses 25.89 Total 214.48
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹184.81 Cr in the year ending 31 Mar 2023, rising to ₹206.45 Cr by 31 Mar 2024, and further increasing to ₹322.58 Cr by 31 Mar 2025. However, the latest figure of ₹236.50 Cr as of 31 Dec 2025 is lower than the prior full year, though this is a 9-month figure, not a full year, so isn't directly comparable.
Profit Trend
Profit After Tax was ₹32.10 Cr for the year ending 31 Mar 2023, increasing to ₹34.44 Cr by 31 Mar 2024, and rising to ₹28.13 Cr by 31 Mar 2025. The latest figure of ₹38.69 Cr as of 31 Dec 2025 shows a positive trend, though this is a 9-month figure, not a full year, so isn't directly comparable.
Grey Market Premium, Explained
The Grey Market Premium (GMP) refers to the unofficial trading of shares before they are listed on the stock exchange. It indicates the expected listing price of the IPO shares compared to the issue price. A positive GMP suggests strong demand for the shares in the grey market.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their overall investment strategy and risk tolerance. It's important to consider the company's fundamentals and market conditions before making a decision.
Who May Want to Wait
Investors who prefer stable, established companies with predictable earnings may want to avoid IPOs like this, which can be more volatile and carry higher risks. It's crucial for such investors to assess their risk appetite before participating.
IPO Timeline, Explained
The IPO process includes several key dates: the opening date for subscriptions is May 21, 2026, and it closes on May 25, 2026. Allotment of shares will be on May 26, 2026, with the listing date set for May 29, 2026.
Listing Gains — The Risk
Listing-day gains can be unpredictable and are influenced by various factors, including market conditions and investor sentiment. While some IPOs may see a surge in price on their listing day, others may not perform as well, leading to potential losses for investors.
This evaluation is generated from Q-Line Biotec's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Q-Line Biotec IPO GMP today?
Q-Line Biotec IPO GMP today is +₹112.0 (32.65%), indicating an estimated listing price of ₹455. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Q-Line Biotec IPO?
The price band of Q-Line Biotec IPO is ₹326.0–₹343.0 per share.
When does Q-Line Biotec IPO open and close?
Q-Line Biotec IPO opens on 21 May 2026 and closes on 25 May 2026.
When does Q-Line Biotec IPO list on the stock exchange?
Q-Line Biotec IPO listed on 29 May 2026 at ₹455.0.
What is the lot size for Q-Line Biotec IPO?
The lot size for Q-Line Biotec IPO is 400 shares, requiring a minimum investment of ₹274,400 (2 lots).
What is the price band for the Q-Line Biotech IPO?
The price band for the Q-Line Biotech IPO is ₹326.0 to ₹343.0.
What is the lot size for the Q-Line Biotech IPO?
The lot size for the Q-Line Biotech IPO is 400 shares.
What is the minimum investment required for the Q-Line Biotech IPO?
The minimum investment required for the Q-Line Biotech IPO is ₹274,400.
When is the listing date for the Q-Line Biotech IPO?
The listing date for the Q-Line Biotech IPO is May 29, 2026.
What does GMP mean in the context of IPOs?
GMP stands for Grey Market Premium, which indicates the expected listing price of the shares compared to the issue price.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
21 May 2026
Close
25 May 2026
Allotment
26 May 2026
Listing
29 May 2026
Similar IPOs in Medical Equipment & Supplies
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Q-Line Biotec?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.